Your Location is set to:

CLEAR Outcomes


The purpose of this study is to determine if treatment with bempedoic acid( ETC-1002), versus a placebo decreases the risk of cardiovascular events in patients who are statin intolerant.  A placebo is made to look like the study drug but has no bempedoic acid.

Principal Investigator(s)
Richard Zelman, MD

Clinical Trial Categories

  • Outpatient Medications
  • Cardiovascular Disease
  • Coronary Disease
Kelcie Brown, RN at
How to Participate

For more information speak with your cardiologist,  primary care physician or contact our experienced research nurse:

                    Kelcie Brown, RN at 508-778-5900


  • Heart & Vascular Institute